查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1870953

植物藥市場按產品類型、劑型、治療領域、通路和最終用戶分類－2025年至2032年全球預測

Botanical Drug Market by Product Type, Formulation, Therapeutic Area, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，植物來源藥物市場將成長至 69.8 億美元，複合年成長率為 7.17%。

關鍵市場統計數據
基準年 2024 40.1億美元
預計年份：2025年 43億美元
預測年份 2032 69.8億美元
複合年成長率 (%) 7.17%

本文對影響植物藥研發的監管壓力、供應鏈韌性和策略專業化進行了簡明扼要的基礎性概述。

植物藥領域融合了傳統藥用植物科學、現代臨床開發和不斷發展的法規結構。為了滿足未被滿足的醫療需求並達到監管核准所需的證據標準，研發人員正日益致力於開發標準化的植物活性成分和特性明確的草藥萃取物。這種發展趨勢正推動該領域從依賴經驗法則的治療方法轉向嚴格的產品特性分析、品管和以臨床為導向的開發路徑。

植物藥業格局的變革性轉變及未來策略重點

植物藥領域正經歷多項變革，這些變革正在重新定義研發重點和商業模式。分析化學和體學技術的進步使研發人員能夠解析複雜的植物性質，識別生物活性成分，並建立以往難以實現的穩定性和功效指標。因此，產品開發過程更加重視標準化的植物活性成分和可重複的萃取方法，以提高法規核准的核准和臨床療效的可預測性。

2025年美國關稅對植物藥材原料、供應鏈及策略採購決策的累積影響

2025年美國關稅政策的實施為植物藥供應鏈帶來了顯著的摩擦，尤其是在植物原料、專用萃取設備和某些中間體方面。進口成本的增加迫使研發人員和原料供應商重新評估其採購基礎和庫存策略。為此，許多企業正在加快供應商多元化計劃，並優先考慮近岸外包機會，以降低關稅波動風險並最大限度地減少前置作業時間風險。

關鍵細分洞察揭示了按產品類型、製劑形式、治療領域、分銷管道和最終用戶分類的商機視窗。

依產品類型細分，可以發現研發和商業化方法上的差異。草藥萃取物正在經歷嚴格的標準化，而複方草藥製劑則利用了協同作用的傳統優勢，但需要先進的分析技術。同時，單味草藥萃取物可以進行更精確的化學表徵，並擁有更清晰的監管路徑。草藥補充劑憑藉其自身的標籤和安全要求，在非處方藥市場保持著一定的佔有率，而標準化的草藥活性成分則為獲得處方級療效和開展臨床開發鋪平了道路。

關鍵區域洞察，包括法規環境、研發能力和市場進入途徑，這些因素將影響重點區域的植物藥策略

在美洲，監管機構強調對具有療效宣稱的植物產品進行嚴格的臨床證據審查和生產控制。同時，完善的藥物監測系統和支付方趨勢創造了一個環境，​​在這種環境下，臨床差異化和衛生經濟學證據對產品的採納有顯著影響。北美生態系統也提供先進的合約研究和生產能力，使申辦者能夠在擁有穩健的供應鏈和明確的監管溝通策略的情況下，加速後期專案的進展。

深入了解植物藥領域主要企業的策略行動、夥伴關係模式與競爭優勢

活躍於植物藥領域的主要企業在分析開發、品質系統和臨床營運等方面展現出不同的能力建構模式。一些企業優先考慮垂直整合（透過合約種植或專有採購安排確保原料供應），而其他企業則專注於模組化夥伴關係，將內部藥物研發與外包委託製造和臨床試驗相結合。這些不同的策略模式反映了對投入要素的控制與快速擴展資源彈性之間的權衡。

為產業領導者提供切實可行的建議，以加強植物性療法開發平臺、降低貿易風險並提高市場準備度

企業應優先考慮分析標準化，並投資於正交表徵技術，以確定活性成分並降低批間差異。透過儘早建立嚴格的化學指紋圖譜和穩定性分析，申辦者可以簡化與監管機構的溝通，並加速從探索性研究到驗證性臨床試驗的過渡。同時，將生物標記策略和患者報告結局納入研究設計，可以增強證據體系，並有助於證明藥物在不同患者群體中具有臨床意義的療效。

調查方法：詳細介紹資料來源、分析架構和檢驗方法，以期對植物來源領域提供可靠的見解。

本研究綜合運用多種檢驗來源，旨在全面了解植物藥產業。主要研究相關人員包括對研發主管、法規事務專業人員、供應鏈經理和商業負責人進行結構化訪談，以收集經驗見解並檢驗新興趨勢。次要資料收集則涵蓋監管指南、同行評審的臨床文獻、生產標準和上市公司披露資訊，以驗證事實論點並分析戰略轉變的背景。

結論：摘要植物療法領域對開發商、監管機構和商業相關人員的策略意義和實踐意義

植物藥領域正處於關鍵的轉折點，科學嚴謹性、供應鏈管理和切實可行的商業化策略共同決定專案的可行性。分析表徵和適應性臨床設計的進步降低了監管核准的技術門檻，但同時也提高了對證據生成和品管系統的要求。因此，成功的計畫必須在科學清晰度和營運穩健性之間取得平衡，以滿足監管機構和臨床相關人員的需求。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 加大研發力度，致力於開發植物藥製劑的標準化萃取方法
  • 擴大基因組為基礎的植物化學型選擇在標靶治療的應用
  • 全球植物藥核准途徑監管協調工作加速推進
  • 將人工智慧預測模型整合到植物化合物的功效和安全性評估中
  • 利用連續流加工技術擴大客製化草藥萃取物的生產規模
  • 開發慢性病綜合治療的多植物協同製劑

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按產品類型分類的植物藥市場

  • 草藥萃取物
    • 複方草藥製劑
    • 單味草本萃取物
  • 草藥補充劑
  • 標準化草藥活性成分

9. 按劑型分類的植物藥市場

  • 膠囊
  • 液體萃取物
    • 糖漿
    • 酊劑
  • 粉末
  • 外用藥物
    • 奶油
    • 凝膠
    • 軟膏

第10章 按治療區域分類的植物藥市場

  • 循環系統
  • 消化器官系統
  • 內分泌系統
  • 呼吸系統
  • 體重管理

第11章 按分銷管道分類的植物藥市場

  • 醫院藥房
  • 網路藥房
    • 消費者
    • 第三方平台
  • 零售藥房

第12章 依最終用戶分類的植物藥市場

  • 診所
    • 一般診所
    • 專科診所
  • 居家醫療
  • 醫院

第13章 各地區的植物藥市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按類別分類的植物藥市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國植物藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Givaudan SA
    • Dr. Willmar Schwabe GmbH & Co. KG
    • Indena SpA
    • Martin Bauer Group GmbH & Co. KG
    • Euromed SA
    • Horphag Research Ltd
    • Sabinsa Corporation
    • PhytoTech Labs Inc.
    • Bioforce AG
    • PhytoLab GmbH & Co. KG
Product Code: MRR-1A1A064C04EA

The Botanical Drug Market is projected to grow by USD 6.98 billion at a CAGR of 7.17% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.01 billion
Estimated Year [2025] USD 4.30 billion
Forecast Year [2032] USD 6.98 billion
CAGR (%) 7.17%

A concise foundational overview that frames regulatory pressures, supply chain resilience, and strategic professionalization shaping botanical drug development

The botanical drug arena occupies an intersection of traditional pharmacognosy, modern clinical development, and evolving regulatory frameworks. Developers increasingly pursue standardized botanical actives and well-characterized herbal extracts to address unmet therapeutic needs while aiming to meet the evidentiary thresholds required for regulatory approval. This evolution has shifted the sector away from anecdotal remedies toward rigorous product characterization, quality control, and clinically oriented development pathways.

Regulatory clarity is a critical driver of industry behavior. Agencies in major markets are refining guidances for botanical drug dossiers, emphasizing reproducible manufacturing, robust safety profiling, and clearly defined active constituents. Consequently, stakeholders invest in advanced analytical platforms, validated manufacturing processes, and targeted clinical programs that can bridge traditional knowledge with contemporary safety and efficacy standards. Investors and strategic partners now evaluate botanical projects against criteria common to conventional drug development, including proof of mechanism, reproducibility of raw material supply, and scalable production.

Operationally, supply chain resilience has risen to the top of strategic agendas. Cultivation best practices, traceability systems, and supplier qualification programs reduce raw material variability while enabling compliance with good manufacturing practices. At the same time, the commercial environment rewards developers who combine clinical diligence with compelling differentiation, such as novel formulation technologies, targeted therapeutic positioning, and strong intellectual property strategies. Taken together, these dynamics set the stage for a period of professionalization and strategic consolidation within the botanical drug sector.

Transformative Shifts Reshaping the Botanical Drug Landscape and Future Strategic Priorities

The botanical drug sector is undergoing several transformative shifts that are redefining R&D priorities and commercial models. Advances in analytical chemistry and omics technologies now allow developers to deconvolute complex botanical matrices, identify bioactive fractions, and establish stability and potency metrics that were previously difficult to achieve. As a result, product development pathways emphasize standardized herbal actives and reproducible extract profiles to increase regulatory acceptance and clinical predictability.

Concurrently, clinical development paradigms are adapting. Sponsors increasingly design hybrid trials that incorporate biomarkers, adaptive elements, and pragmatic endpoints to demonstrate clinically meaningful effects more efficiently. This methodological adaptation reflects a broader willingness to combine traditional evidence bases with contemporary trial designs, enabling a more nuanced appraisal of safety and efficacy in heterogeneous patient populations.

From a commercial perspective, strategic partnerships between ingredient suppliers, contract development and manufacturing organizations, and clinical research providers are tightening. These alliances enable vertically integrated approaches that streamline raw material sourcing, process scale-up, and regulatory submission readiness. Meanwhile, innovation in formulation science has unlocked new delivery formats-such as optimized liquid extracts and targeted topical vehicles-that improve bioavailability and patient adherence. Together, these shifts create a dynamic environment in which scientific rigor, operational excellence, and creative commercialization converge to redefine what success looks like in botanical drug development.

Cumulative Impact of United States Tariffs 2025 on Botanical Drug Inputs, Supply Chains, and Strategic Sourcing Decisions

The tariff environment introduced in the United States in 2025 has introduced measurable friction into botanical drug supply chains, particularly for raw botanical materials, specialized extraction equipment, and certain intermediate inputs. Increased import costs have incentivized developers and ingredient suppliers to reassess their sourcing footprints and inventory strategies. In response, many organizations have accelerated supplier diversification programs and prioritized nearshoring opportunities that reduce exposure to tariff volatility and minimize lead time risk.

These trade policy shifts also have implications for manufacturing economics and clinical trial timelines. Higher landed costs for imported intermediates pressure margin profiles and can require re-negotiation of supply agreements or incremental investment in domestic processing capabilities. Consequently, sponsors are evaluating the cost-benefit of relocating certain upstream activities closer to final manufacturing sites, while also strengthening contractual protections and hedging strategies to manage price uncertainty.

On a strategic level, tariffs have highlighted the importance of vertical integration and resilient procurement strategies. Organizations that can demonstrate validated domestic supply chains and in-country processing are better positioned to maintain continuity for pivotal programs and commercial launches. Moreover, regulatory dossiers that document consistent raw material provenance and validated manufacturing controls gain added competitive advantage in environments where trade policies can disrupt long-standing sourcing relationships. Ultimately, the 2025 tariff landscape underlines the necessity of proactive procurement planning and adaptive manufacturing strategies to sustain momentum in botanical drug development.

Key Segmentation Insights That Reveal Opportunity Windows Across Product Types, Formulations, Therapeutic Areas, Distribution Channels, and End Users

Insight into product type segmentation highlights divergent R&D and commercialization approaches. Herbal extracts are increasingly pursued with rigorous standardization; multi herb formulations continue to leverage synergistic traditions but require heightened analytical justification, while single herb extracts enable tighter chemical characterization and clearer regulatory pathways. Herbal supplements remain prominent in over-the-counter spaces with distinct labeling and safety obligations, and standardized herbal actives represent the bridge toward prescription-level therapeutic claims and clinical development.

Formulation choices materially influence clinical performance and patient acceptance. Capsules and tablets offer dose consistency and manufacturing scalability, liquid extracts provide flexible dosing and rapid onset characteristics with liquid formats further differentiated by syrups and tinctures that address pediatric and adult dosing requirements, powders enable nutritional or compounding versatility, and topicals deliver localized therapy with subcategories such as creams, gels, and ointments that meet specific dermal absorption and patient preference attributes.

Therapeutic area segmentation guides clinical strategy and target selection. Cardiovascular, digestive, endocrine, respiratory, and weight management indications each present unique endpoints, safety considerations, and patient demographics that shape trial design and regulatory engagement. Distribution channel segmentation drives go-to-market mechanics; hospital pharmacy pathways demand formulary evidence and clinical support, online pharmacy models-operated either direct to consumer or via third party platforms-require robust digital marketing and fulfillment capabilities, and retail pharmacy strategies necessitate point-of-sale visibility and pharmacist education programs.

End user segmentation underscores deployment environments and service models. Clinics, inclusive of general and specialty clinics, prioritize standardized dosing and evidence-backed protocols, home care emphasizes ease of administration and adherence-enhancing delivery systems, and hospitals require integration into institutional formularies, sterile manufacturing where applicable, and cross-disciplinary clinical evidence to support therapeutic adoption. These segmentation insights together inform product positioning, clinical investment focus, and channel strategies for botanical drug developers.

Key Regional Insights Showing How Regional Regulatory Environments, R&D Capabilities, and Market Access Pathways Shape Botanical Drug Strategies Across Major Geographies

In the Americas, regulatory authorities emphasize rigorous clinical evidence and manufacturing controls for botanical products that seek therapeutic claims, while established pharmacovigilance systems and payer dynamics create a landscape where clinical differentiation and health economic evidence can materially influence adoption. North American ecosystems also host advanced contract research and manufacturing capabilities, enabling sponsors to accelerate late-stage programs when supply chains are resilient and regulatory engagement strategies are well-defined.

In Europe, Middle East & Africa, regulatory frameworks vary significantly by jurisdiction, requiring regionally tailored dossier strategies and localized quality documentation. Several European regulators accept well-controlled clinical programs that integrate traditional use with contemporary clinical endpoints, while reimbursement environments differ widely and often depend on health technology assessment outcomes. Across the broader region, strategic partnerships with regional manufacturing and clinical research organizations can unlock access to diverse patient populations and cost-effective trial execution.

In Asia-Pacific, robust herbal medicine traditions coexist with rapidly evolving regulatory standards that increasingly harmonize with global best practices. Many markets in the region possess mature botanical supply chains and strong agricultural capacity, which supports scalable raw material sourcing. Additionally, the region's growing investment in biopharmaceutical R&D and contract services presents opportunities for strategic clinical collaborations and cost-efficient manufacturing scale-up, provided sponsors align development plans with local regulatory expectations and quality standards.

Key Companies Insights Highlighting Strategic Behavior, Partnership Models, and Competitive Differentiators in the Botanical Drug Sector

Leading organizations operating in the botanical space demonstrate a pattern of capability building across analytical development, quality systems, and clinical operations. Some companies prioritize vertical integration-securing raw material supply through contracted cultivation or proprietary sourcing agreements-while others focus on modular partnerships that combine in-house discovery with outsourced manufacturing and clinical execution. These different strategic archetypes reflect a trade-off between control over inputs and flexibility to scale resources quickly.

Partnership models frequently pair botanical expertise with clinical research organizations and specialist CMOs to accelerate translational activities from extract standardization to pivotal trials. Firms that invest early in robust quality assurance systems and comprehensive characterization of active constituents create defensible positions when engaging with regulators and payers. Competitive differentiators include proprietary extraction technologies that enhance bioavailability, formulation platforms that enable novel delivery modes, and curated supply chain traceability that mitigates raw material variability.

Company behaviors also reveal a pragmatic balance between niche specialization and portfolio diversification. Some developers concentrate on narrow therapeutic niches where botanical mechanisms align closely with clinical endpoints, enabling clearer differentiation. Others maintain broader portfolios to capture multiple commercial pathways, combining over-the-counter product lines with clinically developed botanical therapeutics. Across the sector, strong intellectual property strategies, quality certifications, and transparent clinical evidence packages remain decisive factors in partner selection and commercial traction.

Actionable Recommendations for Industry Leaders to Strengthen Development Pipelines, Mitigate Trade Risks, and Enhance Market Readiness for Botanical Therapeutics

Companies should prioritize analytical standardization and invest in orthogonal characterization techniques to define active fractions and reduce batch variability. By establishing rigorous chemical fingerprints and stability profiles early, sponsors can streamline regulatory dialogue and accelerate transition from exploratory studies to confirmatory clinical programs. Simultaneously, integrating biomarker strategies and patient-reported outcomes into trial design will strengthen evidentiary packages and help demonstrate clinically meaningful benefit across heterogeneous populations.

To mitigate trade-related risks and tariff exposure, leaders should diversify supplier networks, qualify secondary domestic or regional processors, and consider strategic inventory buffers for critical inputs. Nearshoring key transformation steps and adopting multi-sourcing contracts with explicit quality and delivery clauses will reduce disruption risk and improve control over lead times. In parallel, organizations should pursue manufacturing partnerships that can scale while maintaining validated controls to support both clinical supply and commercial launch readiness.

Commercially, companies must align distribution and engagement models with end user expectations. For hospital and clinic adoption, prioritize clinical education, formulary evidence, and institutional partnerships; for online and retail channels, invest in digital engagement, compliant labeling, and pharmacist or clinician outreach that clarifies therapeutic positioning. Finally, cultivate cross-functional teams that integrate regulatory, clinical, quality, and commercial expertise to ensure development decisions anticipate market access requirements and deliver clear value propositions to payers and providers.

Research Methodology Detailing Data Sources, Analytical Frameworks, and Validation Practices Employed to Deliver Robust Botanical Sector Insights

This research synthesized multiple validated inputs to build a comprehensive understanding of the botanical drug landscape. Primary engagement with industry stakeholders included structured interviews with R&D leaders, regulatory affairs professionals, supply chain managers, and commercial strategists to capture experiential insights and validate emergent trends. Secondary data collection encompassed regulatory guidances, peer-reviewed clinical literature, manufacturing standards, and public company disclosures to triangulate factual assertions and contextualize strategic shifts.

Analytical frameworks combined qualitative thematic analysis with supply chain mapping and regulatory pathway comparison to identify leverage points and risk concentrations. The methodology prioritized traceability of raw material provenance, reproducibility of analytical methods, and alignment between clinical endpoints and regulatory expectations. Cross-validation steps included expert panel reviews and iterative reconciliation of primary and secondary inputs to minimize bias and ensure findings reflect operational realities.

Where applicable, the research applied scenario-based stress testing to examine the operational effects of trade policy shifts, supply disruptions, and formulation transitions. Findings were then synthesized into actionable recommendations that map to distinct corporate functions, enabling practical uptake by product development, quality, and commercial teams.

Conclusion Summarizing Strategic Takeaways and the Practical Implications for Developers, Regulators, and Commercial Stakeholders in Botanical Therapeutics

The botanical drug sector stands at a pivotal juncture where scientific rigor, supply chain discipline, and pragmatic commercialization strategies collectively determine program viability. Advances in analytical characterization and adaptive clinical designs have lowered technical barriers to regulatory acceptance, yet they also raise the bar for evidence generation and quality systems. Therefore, successful programs will couple scientific clarity with operational robustness to satisfy both regulators and clinical stakeholders.

Trade policy dynamics have underscored the importance of resilient sourcing and flexible manufacturing strategies, making procurement and supplier qualification central to program risk management. At the same time, segmentation and regional nuances demand tailored approaches to formulation, distribution, and clinical engagement. Firms that align therapeutic positioning with end user needs and regional regulatory expectations will be better equipped to translate clinical outcomes into clinical uptake.

In sum, the industry's trajectory favors organizations that integrate enhanced analytical capabilities, disciplined supply chain practices, and commercially attuned development plans. These combined strengths will enable botanical drug developers to navigate regulatory challenges, manage external shocks, and capture value through differentiated, evidence-backed therapeutic offerings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing R&D focus on standardized extraction methods for botanical drug formulations
  • 5.2. Rising adoption of genomics-driven selection of plant chemotypes for targeted therapies
  • 5.3. Surge in regulatory harmonization efforts for global botanical drug approval pathways
  • 5.4. Integration of AI predictive modeling in botanical compound efficacy and safety assessment
  • 5.5. Expansion of customized herbal extract manufacturing using continuous flow processing technologies
  • 5.6. Development of multi botanical synergistic formulations for comprehensive chronic disease management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Botanical Drug Market, by Product Type

  • 8.1. Herbal Extracts
    • 8.1.1. Multi Herb Formulation
    • 8.1.2. Single Herb Extract
  • 8.2. Herbal Supplements
  • 8.3. Standardized Herbal Actives

9. Botanical Drug Market, by Formulation

  • 9.1. Capsules Tablets
  • 9.2. Liquid Extracts
    • 9.2.1. Syrups
    • 9.2.2. Tinctures
  • 9.3. Powders
  • 9.4. Topical
    • 9.4.1. Creams
    • 9.4.2. Gels
    • 9.4.3. Ointments

10. Botanical Drug Market, by Therapeutic Area

  • 10.1. Cardiovascular
  • 10.2. Digestive
  • 10.3. Endocrine
  • 10.4. Respiratory
  • 10.5. Weight Management

11. Botanical Drug Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
    • 11.2.1. Direct To Consumer
    • 11.2.2. Third Party Platforms
  • 11.3. Retail Pharmacy

12. Botanical Drug Market, by End User

  • 12.1. Clinics
    • 12.1.1. General Clinics
    • 12.1.2. Specialty Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Botanical Drug Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Botanical Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Botanical Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Givaudan SA
    • 16.3.2. Dr. Willmar Schwabe GmbH & Co. KG
    • 16.3.3. Indena S.p.A.
    • 16.3.4. Martin Bauer Group GmbH & Co. KG
    • 16.3.5. Euromed S.A.
    • 16.3.6. Horphag Research Ltd
    • 16.3.7. Sabinsa Corporation
    • 16.3.8. PhytoTech Labs Inc.
    • 16.3.9. Bioforce AG
    • 16.3.10. PhytoLab GmbH & Co. KG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BOTANICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BOTANICAL DRUG MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BOTANICAL DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BOTANICAL DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BOTANICAL DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BOTANICAL DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BOTANICAL DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BOTANICAL DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BOTANICAL DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BOTANICAL DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MULTI HERB FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MULTI HERB FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MULTI HERB FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MULTI HERB FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MULTI HERB FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MULTI HERB FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SINGLE HERB EXTRACT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SINGLE HERB EXTRACT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SINGLE HERB EXTRACT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SINGLE HERB EXTRACT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SINGLE HERB EXTRACT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SINGLE HERB EXTRACT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BOTANICAL DRUG MARKET SIZE, BY STANDARDIZED HERBAL ACTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BOTANICAL DRUG MARKET SIZE, BY STANDARDIZED HERBAL ACTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BOTANICAL DRUG MARKET SIZE, BY STANDARDIZED HERBAL ACTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BOTANICAL DRUG MARKET SIZE, BY STANDARDIZED HERBAL ACTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BOTANICAL DRUG MARKET SIZE, BY STANDARDIZED HERBAL ACTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BOTANICAL DRUG MARKET SIZE, BY STANDARDIZED HERBAL ACTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULES TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULES TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULES TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULES TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULES TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULES TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TINCTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TINCTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TINCTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TINCTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TINCTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TINCTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BOTANICAL DRUG MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BOTANICAL DRUG MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BOTANICAL DRUG MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BOTANICAL DRUG MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BOTANICAL DRUG MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BOTANICAL DRUG MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIGESTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIGESTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIGESTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIGESTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIGESTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIGESTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ENDOCRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ENDOCRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ENDOCRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ENDOCRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ENDOCRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RESPIRATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THIRD PARTY PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THIRD PARTY PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THIRD PARTY PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THIRD PARTY PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THIRD PARTY PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THIRD PARTY PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BOTANICAL DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BOTANICAL DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS BOTANICAL DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS BOTANICAL DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 328. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 332. MIDDLE EAST BOTANICAL DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 333. AFRICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 334. AFRICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 335. AFRICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. AFRICA BOTANICAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. AFRICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 338. AFRICA BOTANICAL DRUG MARKET SIZE, BY HERBAL EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 339. AFRICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 340. AFRICA BOTANICAL DRUG MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 341. AFRICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2018-2024 (USD MILLION)
  • TABLE 342. AFRICA BOTANICAL DRUG MARKET SIZE, BY LIQUID EXTRACTS, 2025-2032 (USD MILLION)
  • TABLE 343. AFRICA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 344. AFRICA BOTANICAL DRUG MARKET S